Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search


German multinational pharmaceutical, chemical, and agricultural biotechnology company

Bayer is a publicly-traded, multinational company headquartered in Leverkusen, Germany. Founded over 150 years ago, its core competencies presently lie in the life science fields of health care and agriculture.

Business Areas

The company's life science unit has 3 main divisions, pharmaceuticals, consumer health, and crop science. It also has an animal health unit as well as a corporate functions business services unit. Also, Bayer has a 60% stake in Currenta, a company offering services for the chemical industry, including utility supply, waste management, infrastructure, safety, security, analytics, and vocational training.


In terms of sales, Bayer's pharmaceuticals segment is the largest in the company. The focus of this segment is primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology, and ophthalmology. Principal research centers are located in Germany, the United States, Finland, and Norway.

Consumer Health

The consumer health division focuses on everyday healthcare, where the company has a portfolio of over 170 brands to treat minor illnesses. The products are in areas such as digestive health, allergies, skin conditions, pain management, nutritional supplements, and common colds.

Crop Science

Bayer's crop sciences division focuses on delivering solutions to farmers in areas such as crop protection, seeds, and traits, and digital farming. In June 2018, Bayer completed its acquisition of Monsanto for approximately $63 billion. In connection with regulatory approval processes, the company agreed to divest portions of its businesses to BASF.

Animal Health

The company's animal health unit develops and markets products and solutions for the prevention and treatment of diseases in companion and farm animals. In November 2018, Bayer announced its plan to sell the unit, which is estimated to be worth up to €7 billion, along with several other brands. The move is estimated to result in about 12,000 job cuts worldwide.

Business Services

Bayer's business services unit is an in-house center for business solutions and business support process. Its portfolio ranges from the development and implementation of IT-based solutions and design, building, and execution of end-to-end process operations to in-house management consulting.

Bayer LifeHubs

Bayer's LifeHubs are co-working, learning, and incubation spaces managed by Bayer. They are intended to be used by startups and prospective startup companies as a space to collaborate, learn more about industries and industry-specific challenges, and as a general co-working and meeting space. They have locations in Boston, California, Lyon, Berlin, Singapore, Japan, and Reading.


The Bayer CoLaborator program is a startup incubation program. They offer startups co-working spaces located within their LifeHubs and elsewhere. They focus on engagement between life-science startups and Bayer researchers. They have CoLaborator locations in Berlin, Kobe, Moscow, and San Francisco for pharmaceutical startups. They have a location in West Sacramento for crop science startups.


Bayer has supported myAgro, a non-profit investing in and providing services for the development of smallholder farmers. Their initial focus was in Mali. Part of myAgro's work has been enabling farmers to save small amounts for seed and fertilizer through a cellphone for those unable to have a bank account. They also work on nutrition and hygiene seminars and deworming programs.



June 29, 2021
Bayer launches its decarbonization program for agriculture in Europe.
June 8, 2021
Bayer’s Parkinson’s disease stem cell therapy officially lands in the clinic while another treatment for the neurodegenerative movement disorder is seeking patients
June 3, 2021
Bayer announces agreement to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc.
May 18, 2021
Bayer announces that Brett Begemann, Chief Operating Officer, Crop Science, will retire from his role after 38 years with the company and Rodrigo Santos currently Head of Crop Science Commercial Operations, Latin America, will succeed Begemann.
December 1, 2020
Bayer and Blackford Analysis announce AI Platform agreement in Radiology.
November 18, 2020
Bayer and BlockApps launch blockchain initiative TraceHarvest Network - Business Insider.


June 24, 2020
Bayer says it will pay up to US$10.9 billion to settle litigation over the subsidiary Monsanto's weedkiller Roundup, which has faced thousands of lawsuits over claims it causes cancer.
October 1, 2019
Bayer says it is to spend more than 25 billion euros ($27.22 billion) on research and development at its agriculture unit over the next 10 years.

August 7, 2019
Reuters reported last September initial plans by Bayer to divest its 60% stake in the chemical park operator, part of a string of assets it has put on the block to slash debt since its $63 billion takeover of Monsanto last year.
June 2019
Bayer announces that it is planning to invest $5.6 billion over the next 10 years in research on weed control.



Invested in


Further Resources


Bayer | Who We Are


October 1, 2018

Bayer Completes Monsanto Acquisition for $63 Billion


Bayer to cut 12,000 jobs and sell brands



Nick Paul
October 13, 2021
Aum Biosciences is moving on to oncology turf targeted by companies including Bayer and Roche, securing $27 million to take inhibitors of MNK and TRK into midphase clinical trials.
Kyle LaHucik
October 6, 2021
Emile Nuwaysir led the $1 billion bet that Bayer placed on Parkinson's via its BlueRock Therapeutics subsidiary. Now, the chairman of the Alliance for Regenerative Medicine will take the reigns at Ensoma, a gene therapy biotech that launched with $70 million and a Takeda partnership in February.
Andrea Park
September 29, 2021
The latest of Bayer and Huma's joint projects, unveiled this week, has the duo working to build an AI-powered tool to analyze CT scans and improve lung cancer diagnosis.
Kyle LaHucik
September 20, 2021
Bayer will pay up to $253 million in biobucks to use Gubra's machine learning drug discovery tools to find potential treatments for kidney and heart disorders.
Nick Paul
September 20, 2021
Pyxis Oncology is aiming to close out a transformative 2021 with an IPO. Having licensed a pair of antibody-drug conjugates from Pfizer and raised a megaround to develop them, Pyxis is now seeking to tap public investors for cash in an IPO filing that sets the initial fundraising target at $100 million.


Golden logo
By using this site, you agree to our Terms & Conditions.